Serum Urate Lowering Therapy Using Allopurinol Improves Serum 25 Hydroxy Vitamin D in Stage 3-5 CKD Patients: A Pilot Study

Mohammed, Amira; Marie, Mohamed; Abdulazim, Dina O.; Hassan, Mohammed; Shaker, Olfat; Ayeldeen, Ghada; Salem, Mona M; Din, Usama A Sharaf El

doi:10.1159/000512340

Cited by 4 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, uric acid might exert adverse effects on bone health by affecting 25-OH-D (1,25D) and parathyroid hormone (PTH) levels. An inverse correlation between 1,25D concentrations and uric acid has been revealed in the HU model and chronic kidney disorder subjects ( 39 – 41 ). However, this association could be reversed by allopurinol, a drug that lowers uric acid levels ( 41 ).…”

Section: Discussionmentioning

confidence: 94%

“…An inverse correlation between 1,25D concentrations and uric acid has been revealed in the HU model and chronic kidney disorder subjects ( 39 – 41 ). However, this association could be reversed by allopurinol, a drug that lowers uric acid levels ( 41 ). Similarly, serum uric acid was positively correlated with PTH levels ( 39 , 42 ).…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Relationship between bone mineral density and hyperuricemia in obesity: A cross-sectional study

et al. 2023

View full text Add to dashboard Cite

BackgroundObesity is an increasingly severe global public health issue. This study aims to estimate the cross-sectional association between bone mineral density (BMD) and hyperuricemia (HU) in obesity.MethodA total of 275 obese subjects (126 men and 149 women) participated in this cross-sectional study. Obesity was diagnosed as body mass index (BMI) ≥28 kg/m2, whereas HU was defined as the blood uric acid level of 416 μmol/L in men and 360 μmol/L in women. The BMD of the lumbar spine and right hip was measured by dual-energy X-ray absorptiometry (DXA). The multivariable logistic regressions were employed to examine the relationship between BMD and HU in obesity, with the adjustment of gender, age, fasting blood glucose, fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein, creatinine, blood urea nitrogen, high-sensitivity C-reactive protein (hs-CRP), cigarette smoking, and alcohol drinking status.ResultThe overall prevalence of HU was 66.9% in this obese population. The mean age and BMI of this population were 27.9 ± 9.9 years and 35.2 ± 5.2 kg/m2, respectively. The multivariable-adjusted OR (the highest vs. lowest BMD quartile) demonstrated a negative relationship between BMD and HU in total (OR = 0.415, 95%CI: 0.182–0.946; p = 0.036), L1 (OR = 0.305, 95%CI: 0.127–0.730; p = 0.008), L2 (OR = 0.405, 95%CI: 0.177–0.925; p = 0.032), and L3 (OR = 0.368, 95%CI: 0.159–0.851; p = 0.020) lumbar vertebrae. In the subgroup analysis for the male population, the BMD was also negatively associated with HU in total (OR = 0.077, 95%CI: 0.014–0.427; p = 0.003), L1 (OR = 0.019, 95%CI: 0.002–0.206; p = 0.001), L2 (OR = 0.161, 95%CI: 0.034–0.767; p = 0.022), L3 (OR = 0.186, 95%CI: 0.041–0.858; p = 0.031), and L4 (OR = 0.231, 95%CI: 0.056–0.948; p = 0.042) lumbar vertebrae. However, such findings did not exist in women. In addition, there was no significant relationship between hip BMD and HU in obesity.ConclusionOur results showed that the lumbar BMD was negatively associated with HU in obesity. However, such findings only existed in men, rather than women. In addition, no significant relationship between hip BMD and HU existed in obesity. Due to the limited sample size and nature of the cross-sectional design, further large prospective studies are still needed to clarify the issues.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 94%

Relationship between bone mineral density and hyperuricemia in obesity: A cross-sectional study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The current study found that CKD patients with gout have higher prevalences of CKDmetabolic bone disease and degenerative joint disease, indicating that these patients may be particularly vulnerable to bone and joint damage. Prior studies reported higher PTH levels with hyperuricemia in patients with [22][23][24] and without [24][25][26] CKD, possibly due to the suppression of 1α-hydroxylase [27]. However, the causative factor in this relationship remains unclear as PTH may inhibit renal urate excretion [24].…”

Section: Discussionmentioning

confidence: 99%

Prevalence and Influence of Gout in Patients with Advanced Chronic Kidney Disease: Findings of a Large Retrospective Chart Review

Stern,

Johnson,

Shakouri

et al. 2024

GUCDD

View full text Add to dashboard Cite

Gout patients have higher mortality, heavier comorbidity burden, and lower quality of life than non-gout patients, but information is sparse on how gout affects advanced CKD patients. This study examined the prevalence and potential health impacts in stage 3–5 CKD patients. Gout was defined as being listed as a comorbidity, ULT use, and/or reported gout symptoms (tophi, >1 flare). Uncontrolled gout was defined as hyperuricemia (serum urate >6 mg/dL) with tophi, ≥2 gout flares/year, or ≥1 swollen/tender joint. This study included 746 patients (55% men, age: 56.2 ± 18.3 years, CKD-duration: 4.0 ± 4.8 years, eGFR: 32.2 ± 15.5 mL/min/1.73 m2), of which 23% met the gout criteria. Prevalence was highest in patients with stage 3b and 4 CKD. Gout patients had a significantly higher prevalence of cardiovascular comorbidities, CKD-mineral bone disorder, and back pain than non-gout patients. Uncontrolled gout patients had more hypertension, joint issues, chronic pain, febuxostat use, and colchicine use than controlled patients. Compared to those without gout, gout patients had higher rates of cardiovascular and bone diseases, with uncontrolled patients having an even higher burden. In conclusion, these data suggest that identifying and monitoring gout in CKD patients provides health benefits. However, more than one-third of gout patients did not have a formal gout diagnosis in their medical record.

show abstract

“…Additionally, SUA might exert adverse effects on bone health by affecting 1,25D and PTH levels. Several studies have emphasized the inverse correlation between 1,25D concentrations and SUA in hyperuricemic rats 47 and in patients with CKD 48 , 49 , and this association could be reversed after receiving allopurinol to lower SUA levels 49 . Likewise, two observational studies showed that SUA was positively correlated with PTH levels 47 , 50 .…”

Section: Discussionmentioning

confidence: 99%

No association between serum uric acid and lumbar spine bone mineral density in US adult males: a cross sectional study

Yang

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Available evidence linking serum uric acid (SUA) and bone mineral density (BMD) remains controversial, and data on this association are limited among adult men in the general population. Thus, the aim of this study was to evaluate the association of SUA with lumbar spine BMD in US adult males. A cross-sectional study was conducted based on the National Health and Nutrition Examination Survey (NHANES, 1999–2006) database. Multivariate linear regression analyses were employed to assess the association of SUA with lumbar spine BMD, considering complex survey design and sampling weights. Through rigorous eligibility criteria, a total of 6704 individuals were yielded for final data analysis (average age, 40.5 years; 70.6% white). After fully adjusting potential confounders, no associations were detected between SUA and lumbar spine BMD [β (95% confidence interval, CI), − 0.003 (− 0.007, 0.002)]. Additionally, similar results were observed in all stratification analyses, and no interactions were found based on all priori specifications. In brief, our findings did not provide an inspiring clue for the hypothesis that SUA may be beneficial to lumbar spine BMD. Future more prospective studies are needed to further explore the causal relationship of SUA with lumbar spine BMD.

show abstract

Serum Urate Lowering Therapy Using Allopurinol Improves Serum 25 Hydroxy Vitamin D in Stage 3-5 CKD Patients: A Pilot Study

Cited by 4 publications

References 18 publications

Relationship between bone mineral density and hyperuricemia in obesity: A cross-sectional study

Relationship between bone mineral density and hyperuricemia in obesity: A cross-sectional study

Prevalence and Influence of Gout in Patients with Advanced Chronic Kidney Disease: Findings of a Large Retrospective Chart Review

No association between serum uric acid and lumbar spine bone mineral density in US adult males: a cross sectional study

Contact Info

Product

Resources

About